Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma -

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Information type: Randomised controlled trials
Source: New England Journal of Medicine
Specialities: Cancers | Haematological disorders
Summary
RCT (n=569) found PFS at 12 months was 83.2% (95% CI, 78.3 to 87.2) in the daratumumab group (lenalidomide+dexamethasone+daratumumab), as compared with 60.1% (54.0 to 65.7) in the control group (lenalidomide and dexamethasone alone).
UKMi comment
An editorial discusses recent advances in the treatment of multiple myeloma due to an improved understanding of the disease pathogenesis couple with biomarker discovery which has led to a new disease definition.
Related links: Editorial